Home » Advocacy » Letters, Testimony & Comments

Letters, Testimony & Comments

FDA's Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets
April 18, 2011
Re: Docket No. FDA-2011-D-0057: Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets Dear Sir/Madam: The Biotechnology Industry Organization (BIO) thanks the Food and Drug...
Taking Measure of Countermeasures: How Biotechnology Can Help Protect the United States
April 13, 2011
Hearing Testimony Phyllis Arthur Senior Director for Vaccines, Immunotherapeutics and Diagnostics Policy at the Biotechnology Industry Organization (BIO) On behalf of BIO before the House of Representatives Homeland Security Emergency...
Renewable Fuel Standard: BIO Asks Congress to Maintain Commitment
April 13, 2011
Committee on Environment and Public Works United States Senate Oversight Hearing on Domestic Renewable Fuels: From Ethanol to Advanced Biofuels Written Testimony Submitted by  Brent Erickson Executive Vice President, Biotechnology...
Testimony on Rhode Island Labeling Bill
April 13, 2011
Testimony of the Biotechnology Industry Organization (BIO) Hearing of the House Committee on Health, Education and Welfare April 13, 2011 Regarding Rhode Island House Bill 5629: "AN ACT AMENDING THE RHODE ISLAND FOOD, DRUGS, AND...
Clean Energy: Biomass Should Qualify for Standard
April 11, 2011
The Biotechnology Industry Organization ("BIO") is pleased to submit responses to question numbers 1,2, 4, 5, and 6 of the Senate Energy and Natural Resources Committee's March 21, 2011 Clean Energy Standard ("CES") White...
BIO Comments on Implementation of Physician Transparency and Reporting Provisions of PPACA
April 7, 2011
Re: Comments on Section 6002 of the Affordable Care Act Dear Sir or Madam: BIO appreciates the opportunity to comment on the implementation of the Physician Transparency and Reporting provisions enacted in 2010 as part of the Affordable Care...
BIO Comments on FDA's Draft Guidance for Industry on Electronic Source Documentation in Clinical Investigations; Availability
April 7, 2011
Re: Docket No. FDA–2010–D–0643: Electronic Source Documentation in Clinical Investigations Dear Sir/Madam: The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to...
Biotech Leader Provides Testimony at Congressional Hearing on SBIR/STTR Renewal
April 7, 2011
Hearing Testimony Scott Koenig, M.D., PH.D. Before the House of Representatives Committee on Small Business Good morning Chairman Graves, Ranking Member Velázquez, Members of the Committee, ladies and gentleman. I am President and...
Improving the Regulation of Plant Incorporated Protectants: BIO comments on Docket ID No. EPA-HQ-OA-2011-0157
April 4, 2011
E mail - ImprovingRegulations.SuggestionBox@epa.gov RE: Docket ID No. EPA-HQ-OA-2011-0157 (Improving Regulations: Pesticides) and EPA-HQ-OA-2011-0156 (Improving Regulations: General), 76 Fed.Reg. 9988 (February 23, 2011); To whom it may...
Strategy for American Innovation: BIO Comments to the U.S. Department of Commerce
April 1, 2011
Re: Request for Comments on the Strategy for American Innovation Subject: Innovation Strategy RFI Email: competitiveness@doc.gov Dear Mr. Connor: The Biotechnology Industry Organization (BIO) appreciates the opportunity to respond to this...
The American Research and Competitiveness Act: BIO supports the Research and Development Tax Credit
March 24, 2011
On behalf of the Biotechnology Industry Organization (BIO) and its more than 1,100 member companies, academic institutions, state biotechnology centers and related organizations in all 50 states, I am writing to express our strong support for H.R...
Coalition Urges Enactment of Patent Reform Legislation to Drive Job Growth and Innovation
March 24, 2011
March 24, 2011 As our economy begins to improve, job creation remains a critical priority toward ensuring a broad, deep and sustained recovery. To that end, legislation to strengthen our patent system will drive job growth by encouraging...
Comments in Opposition to a North Dakota Proposed Vaccine Purchase Program
March 23, 2011
Statement Opposing S.B. 2276 The Biotechnology Industry Organization (BIO) respectfully submits the following statement in opposition to the universal vaccine purchase program set forth in Senate Bill 2276. While we recognize that the state is...
BIO, AUTM and CropLife International File Joint Brief in Microsoft v. i4i
March 18, 2011
_________________ MICROSOFT CORPORATION, Petitioner, v. I4I LIMITED PARTNERSHIP AND INFRASTRUCTURES FOR INFORMATION, INC., Respondents. _________________ On Writ of Certiorari to the United States Court of Appeals for the Federal Circuit...
BIO Comments on FDA Transparency Initiative: Improving Transparency to Regulated Industry
March 8, 2011
Re: Docket No. FDA-2009-N-0247-0260: FDA Transparency Initiative: Improving Transparency to Regulated Industry Dear Sir/Madam: The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to...
BIO comments on Appendix 3 of the Report on the Facilitated Work Session (CX/FL 11/39/13) of the Codex Committee on Food Labeling (CCFL
March 4, 2011
RE: Request for comments on Appendix 3 of the Chairperson’s Report on the November 15-16, 2010 Facilitated Work Session of the Codex Committee on Food Labeling on the topic of the Labeling of Foods and Food Ingredients Obtained through...
BIO comments on Draft Environmental Assessment: Use of Genetically Modified, Glyphosate-Tolerant Soybeans and Corn on National Wildlife Refuge Lands in the Mountain-Prairie Region
March 4, 2011
Re: Draft Environmental Assessment: Use of Genetically Modified, Glyphosate-Tolerant Soybeans and Corn on National Wildlife Refuge Lands in the Mountain-Prairie Region (Region 6) Dear Colleague: These comments are submitted by the...
BIO’s Comments on the Centers for Medicare and Medicaid Services (CMS) 2012 Draft Call Letter
March 4, 2011
Re: Draft 2012 Part D Call Letter Dear Administrator Berwick: The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the Centers for Medicare & Medicaid Services’ (CMS) Draft 2012 Call Letter. BIO is...
BIO Testifies at FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology
March 2, 2011
Re: Docket No. FDA–2011–N–0002: Advisory Committee for Pharmaceutical Science and Clinical Pharmacology; Notice of Meeting Dear Sir/Madam: On behalf of the Biotechnology Industry Organization (BIO), thank you for the...
Value-based Insurance Design in Connection with Preventive Care Benefits
March 1, 2011
HHS-OS-2010-002: Request for Information Regarding Value-based Insurance Design in Connection with Preventive Care Benefits The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the design aspects of preventive...